Local Institution

Pontoise 95300

0 studies enrolling now · 2 studies all time

What they study most

Congestive Heart Failure, Lung Cancer

Studies at this site

• A Dose Frequency Optimization,Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer Who Received Up to 12 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks — Completed
• Irbesartan in Heart Failure With Preserved Systolic Function (I-Preserve) — Completed